Procalcitonin levels in septic and nonseptic subjects with acute kidney injury (AKI) and end-stage kidney disease (ESKD) prior to and during continuous kidney replacement therapy (CKRT)
Authors' conclusion
Procalcitonin levels are markedly elevated in nonseptic critically ill patients with either AKI or ESKD and do not effectively distinguish sepsis from nonseptic status prior to or during CKRT.
Study context
- Population
- Critically ill septic or nonseptic patients with AKI or ESKD requiring CKRT (continuous venovenous hemodialysis); sepsis defined by culture results111 plasma measurements
- Participants
- 41 participants
- Exposure
- Septic vs nonseptic patients with AKI or ESKD
- Outcome
- Ability of plasma procalcitonin to distinguish septic from nonseptic status prior to or during CKRT
Main finding
As reported in the abstract
Plasma procalcitonin prior to CKRT · pre-CKRT
Septic AKI vs Nonseptic AKI: P = 0.03 · Septic ESKD vs Nonseptic ESKD: P = 0.79
- Plasma procalcitonin measurements ≥ 0.5 ng/mL among nonseptic patients
- 92% (66/72)
Observational data: associations, not effects.
Further findings
Procalcitonin clearance during CKRT · days 1, 2, and 3 of CKRT
- Sieving coefficient (effluent ≈20% of plasma levels)
- 0.2
- Plasma procalcitonin did not significantly decline during CKRT in AKI or ESKD
Original publication
Procalcitonin levels in septic and nonseptic subjects with AKI and ESKD prior to and during continuous kidney replacement therapy (CKRT). Crit Care. Published 30 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →